Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

33%

Ph not_applicable

33%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Detailed Status

Completed2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (33.3%)

Phase 31 (33.3%)

N/A1 (33.3%)

Trials by Status

completed267%

active_not_recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

active_not_recruitingphase_2

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)

NCT06997367

completedphase_3

Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants

NCT04351685

completednot_applicable

Heterologous Effects of BCG in Healthy UK Adults

NCT02380508

Clinical Trials (3)

Showing 3 of 3 trials

NCT06997367Phase 2

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)

Active Not Recruiting

NCT04351685Phase 3

Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants

Completed

NCT02380508Not Applicable

Heterologous Effects of BCG in Healthy UK Adults

Completed

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3